New Delhi: The Supreme Court has given the go-ahead to Natco Pharma for launching its generic version of Risdiplam in India, dismissing the appeal filed by Swiss drugmaker F. Hoffmann-La Roche that sought to restrain the Hyderabad-based company.

Risdiplam, an oral therapy prescribed for spinal muscular atrophy (SMA) in patients aged two months and above, is covered under Roche’s patent titled “compounds for treating spinal muscular atrophy.” The company claims a valid “species patent” for Risdiplam, the active pharmaceutical ingredient (API) in its branded product Evrysdi, which is marketed globally, including in India.

A Bench led by Justice P.S. Narasimha declined to interfere with last week’s Delhi High Court order, which had refused to impose any restraint on Natco. The apex court f

See Full Page